Symptomtext
No additional AEs were reported; The patient received first MMR II and VARIVAX on 1/3/2023 and second MMR II and VARIVAX on 1/16/2023.; This spontaneous report has been received from another health professional referring to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, previous drug reactions, allergies, or concomitant medications were not reported. On 03-JAN-2023 the patient was vaccinated with the first dose of varicella virus vaccine live (oka/merck) (VARIVAX) (lot #U015682 had been verified to be a valid number; expiration date 18-MAY-2023, and upon internal validation established as the same date) and measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (lot #U039664 had been verified to be a valid number; expiration date 15-DEC-2023, and upon internal validation established as the same date) both vaccines administered for prophylaxis (dose, vaccination scheme, frequency, route of administration, anatomical site of injection, lot number, and expiration date were not reported). Other suspect therapies included sterile diluent (STERILE DILUENT). On 16-JAN-2023, 14 days after the first dose the patient was vaccinated with the second dose of varicella virus vaccine live (oka/merck) (VARIVAX) (lot #U015682 had been verified to be a valid number; expiration date 18-MAY-2023, and upon internal validation established as the same date) and measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (lot #U039664 had been verified to be a valid number; expiration date 15-DEC-2023, and upon internal validation established as the same date) both vaccines administered for prophylaxis (dose, vaccination scheme, frequency, route of administration, anatomical site of injection, lot number, and expiration date were not reported) (inappropriate schedule of product administration). Other suspect therapies included sterile diluent (STERILE DILUENT). There was no adverse effect reported.